Remi Laliberte

📘 New publication! CARB-X product developer Trellis Bioscience Inc. completed a first-in-human phase 1 clinical study that supports the further development of TRL1068 for the treatment of biofilm-associated infections, including medical device-associated infections and bacteremia. TRL1068 is a native human monoclonal antibody that disrupts bacterial biofilms with broad-spectrum activity against both Gram-positive and Gram-negative species. Evidence of efficacy, safety and pharmacokinetic data from this phase 1 study will help guide future phase 2 and 3 studies of TRL1068. 🔗 Read here: bit.ly/3LM3Avb #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology 

42

1 Comment

𝐒𝐨𝐦𝐞 𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐚𝐥, 𝐌&𝐀 𝐚𝐧𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐏𝐚𝐬𝐭 𝐓𝐰𝐨 𝐖𝐞𝐞𝐤𝐬: BIOVECTRA 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝘀 𝘁𝗵𝗲 𝗺𝗲𝗿𝗴𝗲𝗿 𝘄𝗶𝘁𝗵 Agilent Technologies (𝗗𝗲𝗮𝗹 𝗩𝗮𝗹𝘂𝗲: $𝟵𝟮𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻) Biovectra is a leading CDMO based primarily out of Canada and has been owned by HIG Capital since 2019. Team there seems to have done a great job to grow and scale that business over the past 5 years. Minaris Regenerative Medicine 𝗶𝘀 𝗮𝗰𝗾𝘂𝗶𝗿𝗲𝗱 𝗯𝘆 Altaris, LLC (𝗗𝗲𝗮𝗹 𝗩𝗮𝗹𝘂𝗲: 𝗨𝗻𝗱𝗶𝘀𝗰𝗹𝗼𝘀𝗲𝗱) Minaris, previously Hitachi ATS and prior to that PCT founded by Robert Preti in the late 90s. Actually one of the first Cell & Gene Therapy CDMOs - a move that helps Altaris move further into the CGT space. Dermavant Sciences 𝗮𝗰𝗾𝘂𝗶𝗿𝗲𝗱 𝗯𝘆 Organon (𝗗𝗲𝗮𝗹 𝗩𝗮𝗹𝘂𝗲: $𝟭.𝟮 𝗯𝗶𝗹𝗹𝗶𝗼𝗻) Dermavant, focused on developing and commercialising innovative therapeutics in dermatology, has been acquired by Organon. This acquisition seems to align nicely with their overall mission to meet unmet needs in skin health. Bain Capital 𝗜𝗻𝘃𝗲𝘀𝘁𝘀 $𝟮𝟬𝟬 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻𝘁𝗼 Serán BioScience Although not the Primary investor, Bain Capital has invested $200 million into Seran to support the build a new commercial facility in Bend, Oregon. Vivo Capital remains the majority shareholder of Seran. #Investment #LifeSciences #Insights

22

3 Comments

Curious about the latest in Cell Therapy?🔬 It is inspiring to see the progress in Science and its potential to transform Healthcare. Take a look at these interesting updates and stay informed about the future of Medicine. #medicine #celltherapy

3

Loved talking about how to best train people for the bioeconomy. Thanks for the opportunity Ontario Genomics. A few things I spoke about and also learned: - Project and financial management skills are crucial. 💲📊 - In the design-build-test-learn cycle, skills in "test" are the most important. A lot of "build" will be, or already is, automated 🤖 - Experiential projects and team-based learning are key. Find every opportunity to try this out. No "real world" project is done alone. 👍 - Advocate for yourself! 🙂

45

2 Comments

Come meet Chad and I to discuss your drug development needs

26

Zentek and Triera Biosciences Ltd. Receive $1.1 Million Government of Canada Contract to Test Multivalent Aptamer Technology GUELPH, ON / ACCESSWIRE / November 6, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has received a $1.1 million Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza ("HPAI") A(H5N1). Highlights: The Government of Canada has identified the life sciences sector as a priority of the Canadian economy and is seeking advanced medical technology solutions to address ongoing challenges Triera was awarded a $1.1 million Government of Canada R&D contract through Innovation, Science and Economic Development Canada's ("ISED") Innovative Solutions Canada ("ISC") program:  Health Advanced And Emerging Medical Technologies Triera's multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform Government of Canada testing partners include Health Emergency Readiness Canada ("HERC") within ISED, and Defence Research and Development Canada ("DRDC"), the science and technology organization of the Department of National Defence ("DND") The test will help develop a prophylactic and therapeutic for HPAI A(H5N1) following the multivalent aptamer strategy that successfully produced a SARS-CoV-2 aptamer Triera has proven the capability of the multivalent aptamer platform by developing a universal therapeutic and prophylactic that is effective against all variants of SARS-CoV-2. The contract will allow Triera to prove the capability for developing a lead candidate for HPAI A(H5N1). HERC is a new federal organization within ISED dedicated to protecting Canadians against future pandemics and delivering on Canada's life sciences and medical countermeasures readiness objectives. HERC will provide a sustained focus on advancing life sciences industrial capabilities and innovation to respond to health threats, building on significant achievements in the sector since 2020, including $2.2B that has been invested under Canada's Biomanufacturing and Life Sciences Strategy. DRDC is Canada's defence science, technology, and innovation leader. DRDC develops and delivers new technical solutions and advice to the DND, the Canadian Armed Forces, and safety and security communities. This is accomplished by working with partners in industry, academia, other government departments and international allies. The contract requires Triera to develop a lead candidate for HPAI A(H5N1) within six months of the project initiation. The lead candidate will be tested for its efficacy as a therapeutic and prophylactic along with its safety profile by the Miller Laboratory at McMaster University.

9

Solopharm has been operating its own R&D department since 2014. It provides full cycle pharmaceutical development: from an idea to the implementation of a technology into production. #solopharm #pharma #development #research #researchanddevelopment #production #technology

8

𝐃𝐞𝐰𝐩𝐨𝐢𝐧𝐭 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐌𝐢𝐭𝐬𝐮𝐛𝐢𝐬𝐡𝐢 𝐓𝐚𝐧𝐚𝐛𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐞 𝐨𝐧 𝐀𝐋𝐒 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Dewpoint Therapeutics Inc. Dewpoint Therapeutics has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) Mitsubishi Tanabe Pharma Corporation to advance Dewpoint's novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS). Under the agreement, Dewpoint will receive an upfront payment and is eligible for milestone payments totaling up to $480 million. MTPC holds an exclusive option to license the program for global clinical development and commercialization. This collaboration aims to address the mislocalization of TDP-43, a protein implicated in over 97% of ALS cases. Dewpoint's c-mod targets TDP-43 condensates, restoring the protein's normal function and potentially mitigating neuronal dysfunction in ALS patients. MTPC's expertise in ALS, including the development of FDA-approved therapies for sporadic ALS, complements Dewpoint's innovative approach. The partnership seeks to accelerate the clinical development of this treatment, offering hope to those affected by this debilitating disease. This collaboration underscores the potential of targeting biomolecular condensates in developing novel therapeutics for neurodegenerative diseases. By combining Dewpoint's platform with MTPC's clinical capabilities, the partnership aims to bring a promising treatment to ALS patients worldwide. #ALSResearch #BiotechCollaboration #NeurodegenerativeDiseases #TDP43 #CondensateModulators #PharmaPartnerships #ALS #MitsubishiTanabe #DewpointTherapeutics

1

Hold my beer, eh! This breakthrough was years in the making … and it’s big. For my non-scientist contacts I will try to explain simply why these Canadian researchers may have just changed the game for one important slice of biotech and pharma. It could mean a radical short-cut to better therapies and diagnostic tests, based on antibodies. Antibodies are naturally produced in the body in response to infection and other diseases. The immune system has evolved over Billions of years to do this effectively. In a span of just a couple of weeks it produces and tests perhaps 1,000,000,000,000,000,000 antibodies. If you want to visualize that number, imagine counting all the grains of sand on all the beaches and deserts on earth. The best ones are selected and produced to fight the disease. They are incredibly effective in moving through the body and binding to their target, then either simply blocking the offensive or recruiting other parts of the immune system. Antibodies can be used as amazing tools for healthcare. An antibody can be a made into drug that only targets specific diseased cells, or blocks a specific virus. Think of a test strip that shows a clear signal only when the antibody binds its target. Many of the biggest blockbuster drugs are antibody based. It’s no wonder then, that billions of dollars are spent trying to find the perfect antibodies to use as therapies for the next disease target. But how? We can try to replicate nature - generate sequences (using AI maybe), produce and test them. Or we can try to see if lab animals will produce useful antibodies - but then what? Will these synthetic or animal antibodies be safe to use in humans? Will they be stable and effective? Years of costly R&D is involved in resolving these questions and the failure rate is very high. For every successful new therapy there are hundreds of failed programs and billions of dollars spent. So why not start with antibodies that are already known to be safe, stable and effective in a human - simply by using antibodies extracted from a human patient who has recovered from the disease?! If you think this idea is almost too obvious, you aren’t alone. In fact, physicians have been using blood from recovered patients to treat sick ones for a long time (read about Convalescent Plasma Therapy). But there’s no scalable supply of such plasma. So the problem is finding the antibody you need out of incredibly complex human biology, so you can test it, produce more of it and distribute it to thousands of patients. The solution is to isolate and sequence the important antibodies, then study them and produce more of them. My colleagues have created groundbreaking technology for sequencing antibody proteins out of the complex mixture in human blood. In this Nature Communications paper they show how it works, and that antibodies they produced this way work well to neutralize COVID for example. #biotech #canadianinnovation #antibodies #drugdiscovery #nextgenmedicine

11

An interesting development in the Canadian Biotechnology Sector.

6

We're proud to support Mesentech, a pioneering Vancouver-based biotech startup, to innovate targeted drug delivery with their cutting-edge small molecule therapeutics. Their first clinical program, aimed at promoting musculoskeletal tissue regeneration, is set to have a significant impact while minimizing organ toxicity.     Dr. Gang Chen, Director of Medicinal Chemistry at Mesentech, beautifully captures the value of using ChemAIRS from Chemical.AI: “𝘜𝘵𝘪𝘭𝘪𝘻𝘪𝘯𝘨 𝘊𝘩𝘦𝘮𝘈𝘐𝘙𝘚 𝘧𝘳𝘰𝘮 𝘊𝘩𝘦𝘮𝘪𝘤𝘢𝘭.𝘈𝘐 𝘪𝘴 𝘢𝘯𝘢𝘭𝘰𝘨𝘰𝘶𝘴 𝘵𝘰 𝘪𝘯𝘤𝘰𝘳𝘱𝘰𝘳𝘢𝘵𝘪𝘯𝘨 𝘢 𝘤𝘩𝘦𝘮𝘪𝘴𝘵 𝘸𝘪𝘵𝘩 𝘥𝘦𝘤𝘢𝘥𝘦𝘴 𝘰𝘧 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘪𝘯𝘵𝘰 𝘺𝘰𝘶𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘵𝘦𝘢𝘮. 𝘛𝘩𝘦𝘴𝘦 𝘴𝘶𝘨𝘨𝘦𝘴𝘵𝘦𝘥 𝘳𝘦𝘢𝘤𝘵𝘪𝘰𝘯𝘴 𝘢𝘳𝘦 𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭𝘭𝘺 𝘱𝘭𝘢𝘶𝘴𝘪𝘣𝘭𝘦, 𝘵𝘩𝘰𝘶𝘨𝘩 𝘵𝘩𝘦𝘺 𝘮𝘢𝘺 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘱𝘳𝘦𝘷𝘪𝘰𝘶𝘴𝘭𝘺 𝘦𝘮𝘱𝘭𝘰𝘺𝘦𝘥 𝘵𝘰 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘻𝘦 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘴".    By leveraging ChemAIRS' advanced retrosynthesis and condition search capabilities, Mesentech is speeding up the creation of innovative synthetic routes, optimizing processes with cost-effective materials, and significantly reducing waste. The flexibility of ChemAIRS empowers their chemists to quickly adapt to project needs, ensuring that every step from concept to execution is as efficient and effective as possible. Read the full case study below.    #Biotech #Innovation #AI #DrugDevelopment #ChemicalAI #Mesentech #SyntheticChemistry #Pharma

12

We treat all our samples and analyses with the rigor and precision they deserve. 🧪That's why, as a bioanalytical CRO, the Custom Biologics lab is proud to be: ☑️Health Canada cGMP compliant ☑️Approved to handle and test drugs via our Drug Establishment Licence ☑️FDA 21 CFR Parts 11 and 58 compliant ☑️Dedicated to: 🔹Exceptional Science. Uncompromising Quality🔹 Want to know more about our accreditations, QA program, equipment, or assays we offer? Learn more: https://buff.ly/47pxJtb #bioanalysis #CRO #bioanalytical #bioassays #bioanalyticallab #qualityassurance #cGMP #drugestablishmentlicence

14

Download the new ebook from BPS Bioscience Inc. to learn about the basics of the PARP family and their role in cancer, various ways to measure PARP enzymatic activity, how to optimize PARP assays. #AD https://ow.ly/Ntgq50QI2jM

5

#LSBCmember NEWS: Reverb Therapeutics to Collaborate With Royalmount Laboratories • Laboratoires Royalmount on Development of Advanced Bispecific Antibodies Read more here: https://lnkd.in/gdZ8NTkc

20

this announcement represents a lot of hard work behind the scenes to ensure we (as Canadians ) are better prepared for future pandemics but at the same time, ensuring Canada has an outlet to manufacture the next generations of biologic therapies for a wide array of disease from cancer to neurodegenerative diseases and everything between). We will soon have greater infrastructure to deliver therapeutics to the patient quickly and domestically . Canadian innovation is World class and we are building a new outlet to support the innovators from Canada and around the World. Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada, #ADC, #antibodies, #biologics

30

2 Comments

BPS Bioscience Inc.'s luciferase assay systems (both ONE-Step and TWO-Step Luciferase (Firefly & Renilla) Assay System) are: 💥 Sensitive - highly sensitive detection of firefly luciferase activity. 💥 Stable - the signal is stable for more than two hours, providing flexibility regarding incubation time. 💥 Convenient - simple one-step, homogeneous protocol 💥 High throughput  - the one-step protocol minimizes handling steps to support high-throughput screening applications. 💥 Compatibility - works well with a variety of common media containing 0-10% serum and phenol red. 💥 Instrumentation - does not require a luminometer with injectors. ONE-STEP Luciferase Assay System: The One-Step Luciferase Assay System is designed to be used for high-throughput, sensitive quantitation of firefly luciferase activity in mammalian cell culture. TWO-Step Luciferase (Firefly & Renilla) Assay System The TWO-Step Luciferase (Firefly & Renilla) Assay System is designed to be used for high-throughput, rapid quantitation of both Firefly and Renilla luciferases from a single sample in mammalian cell culture. More information here: https://lnkd.in/er5YKdM6 #luciferase #assaysystem #research #lifescience

21

🚀 Exciting News from Brampton Hospital in Canada! 🚀 We are thrilled to share that a hospital in the Greater Toronto Area is the first in Canada to offer in-house liquid biopsy services, revolutionizing cancer research. This breakthrough is powered by the Ion Torrent Genexus System and the Oncomine Precision Assay, enabling rapid, accurate, and non-invasive biomarker testing.🔬 Why the Genexus System? - Automated Rapid Workflow: From specimen to genomic profile in just one day. - Comprehensive Coverage: Analyzes key biomarkers with high precision. - Efficiency: Minimal DNA input with a rapid turnaround time. 🧬 Oncomine Precision Assay: A game-changer in liquid biopsy research, providing detailed insights into cancer genomics with unmatched accuracy. 📽️ Watch the full video to learn more about this incredible achievement and see how the Genexus System and Oncomine Precision Assay are transforming cancer research in Canada. #CancerResearch #LiquidBiopsy #GenexusSystem #OncominePrecisionAssay #InnovationInHealthcare #ThermoFisherScientific

6